The approval in the second-line EGFR- and MET-altered setting was based on results from the SACHI trial, which compared Orpathys and Tagrisso against chemo.

The company is developing treatments for autism and substance use disorders tailored to patient subgroups identified by clinico-genomic signatures.

For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...

UCLA-led investigators say additional research is needed into why guideline-recommended genetic testing remains low among ...

The agency will allow BMS to discontinue REMS programs for both therapies and reduce certain patient monitoring requirements.

The firm will take a different reimbursement strategy for the test than its prior owner Biocept, which stopped selling it after filing for bankruptcy in 2023.

The company said the therapy is the first allogenic therapy developed with its Tmod technology to be tested in humans.

NEW YORK – Politicians and healthcare administrators in Washington have recently spoken out against direct-to-consumer pharmaceutical advertising, but experts say the latest legislative attempt to ban ...

NEW YORK – Allarity Therapeutics has begun dosing patients in a Phase II trial studying its dual PARP and WNT pathway inhibitor stenoparib in patients with advanced, recurrent, platinum-resistant or ...